A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Forero-Torres, Andres [1 ]
Bartlett, Nancy L. [2 ]
Nasta, Sunita D. [3 ]
Northfelt, Donald [4 ]
Beaven, Anne [5 ]
Myint, Han [6 ]
Whiting, Nancy C. [7 ]
Drachman, Jonathan G. [7 ]
Moskowitz, Craig H. [8 ]
机构：
[1] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[3] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Mayo Clin Arizona, Scottsdale, AZ USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] Univ Colorado, Aurora, CO USA
[7] Seattle Genet Inc, Bothell, WA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：243 / 244
页数：2
相关论文
共 50 条
  • [11] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [12] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
    Martin, Alejandro
    Redondo, Alba M.
    Dlouhy, Ivan
    Salar, Antonio
    Gonzalez-Barca, Eva
    Canales, Miguel
    Montes-Moreno, Santiago
    Ocio, Enrique M.
    Lopez-Guillermo, Armando
    Caballero, Dolores
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
  • [13] Phase II study of dose-adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B-cell lymphoma patients
    Yamasaki, Satoshi
    Kada, Akiko
    Choi, Ilseung
    Iida, Hiroatsu
    Sekiguchi, Naohiro
    Harada, Naoko
    Sawamura, Morio
    Shimomura, Takeshi
    Komeno, Takuya
    Yano, Takahiro
    Yoshida, Isao
    Yoshida, Shinichiro
    Sunami, Kazutaka
    Hishita, Terutoshi
    Takatsuki, Hiroshi
    Ohshima, Koichi
    Takeshita, Morishige
    Saito, Akiko M.
    Iwasaki, Hiromi
    Nagai, Hirokazu
    EJHAEM, 2020, 1 (02): : 507 - 516
  • [14] Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Phelan, James D.
    Huang, Da Wei
    Wright, George
    Simard, Jillian
    Muppidi, Jagan
    Thomas, Craig J.
    Ceribelli, Michele
    Tosto, Frances A.
    Yang, Yandan
    Xu, Weihong
    Davies-Hill, Theresa
    Pack, Svetlana D.
    Peer, Cody J.
    Arisa, Oluwatobi
    Mena, Esther
    Lindenberg, Liza
    Bergvall, Ethan
    Portell, Craig A.
    Farah, Rafic J.
    Lee, Seung Tae
    Pradhan, Amynah
    Morrison, Candis
    Tadese, Atekelt
    Juanitez, Anna Marie
    Lu, Crystal
    Jacob, Allison
    Simmons, Heidi
    Figg, William D.
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (23): : 2143 - 2155
  • [15] Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
    Bartlett, Nancy L.
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Bergua, Juan-Miguel
    Bouabdallah, Krimo
    Forward, Nicholas
    Bijou, Fontanet
    Macdonald, David
    Portell, Craig A.
    Ghesquieres, Herve
    Nowakowski, Grzegorz
    Yasenchak, Christopher A.
    Patterson, Monica
    Ho, Linda
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Kim, Jeong-A
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
  • [16] PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Rozman, S.
    Grabnar, I.
    Novakovic, S.
    Mrhar, A.
    Novakovic, B. Jezersek
    HAEMATOLOGICA, 2017, 102 : 688 - 688
  • [17] A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ward, Jeffrey P.
    Thein, Jessica
    Luo, Jingqin
    Wagner-Johnston, Nina D.
    Cashen, Amanda F.
    Fehniger, Todd A.
    Bartlett, Nancy L.
    BLOOD, 2015, 126 (23)
  • [18] Azacytidine plus rituximab-gemcitabine-oxaliplatin as salvage treatment in patients with relapsed/ refractory diffuse large B-cell lymphoma
    Meng Fanqiao
    Xiang Maoyuan
    Peng Cuicui
    Liu Yu
    Zeng Dongfeng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S453 - S453
  • [19] Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial
    Witzens-Harig, Mathias
    Viardot, Andreas
    Keller, Ulrich
    Buske, Christian
    Crombe, Anne
    Hoenig, Elisabeth
    Atta, Johannes
    Schmier, Johann
    Meissner, Julia
    Ho, Anthony D.
    LaRosee, Paul
    Marks, Reinhard
    Dreyling, Martin
    Hess, Georg
    BLOOD, 2016, 128 (22)
  • [20] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
    Kayoko Murayama
    Toru Kiguchi
    Koji Izutsu
    Yoshihiro Kameoka
    Michihiro Hidaka
    Harumi Kato
    Shinya Rai
    Junya Kuroda
    Kenichi Ishizawa
    Satoshi Ichikawa
    Kiyoshi Ando
    Michinori Ogura
    Koji Fukushima
    Yasuhito Terui
    Annals of Hematology, 2022, 101 : 979 - 989
12345